Limb-Sparing Surgery Plus Radiotherapy May Improve Survival Outcomes in Soft-Tissue Sarcoma

Share this content:
Limb-sparing surgery plus radiotherapy, now considered the standard of care to treat patients with extremity soft-tissue sarcoma, leads to improved outcomes, confirmed a recent trial.
Limb-sparing surgery plus radiotherapy, now considered the standard of care to treat patients with extremity soft-tissue sarcoma, leads to improved outcomes, confirmed a recent trial.

Limb-sparing surgery (LSS) plus pre- or postoperative radiotherapy (RT) may lead to improved overall survival (OS) and sarcoma mortality (SM) among patients with high-grade, extremity soft-tissue sarcoma (E-STS), according to a study published in Cancer Medicine.1

A previous study demonstrated that LSS plus RT, now considered the standard of care, leads to improved outcomes among patients with E-STS. Subsequent studies however, produced conflicting results, did not include modern patient data, and were often underpowered.

For this study, researchers accessed the National Cancer Database (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) Program to evaluate the cases of 7828 and 2937 patients with E-STS, respectively. Eligible patients had stage II to III, high-grade E-STS, and were diagnosed between 2004 and 2013. Investigators studied the outcomes of patients who underwent amputation alone, LSS alone, preoperative RT plus LSS, or LSS plus postoperative RT. Approximately 30% to 35% of patients underwent amputation or LSS alone.

Multivariable analyses showed that patients who underwent amputation were associated with significantly inferior OS and SM compared with patients exposed to LSS alone (NCDB: hazard ratio [HR], 1.31; 95% CI, 1.13-1.51; SEER: HR, 1.59; 95% CI, 1.24-2.04).

Results from NCDB and SEER databases demonstrated that preoperative RT plus LSS (HR, 0.70; 95% CI, 0.62-0.78) and LSS plus postoperative RT (HR, 0.69; 95% CI, 0.63-0.75) prolonged OS and reduced SM compared with LSS alone.

Matched-pair analyses revealed that the median survival was 7.2 years among patients treated with LSS alone compared with 9.8 years among patients treated with LSS plus postoperative RT. Results were similar with preoperative RT plus LSS; patients who received LSS alone had a median survival of 6.6 years compared with 8.9 years among patients who underwent preoperative RT plus LSS.

The authors concluded that “LSS combined with RT is the optimal treatment option for most patients with high‐grade E‐STS.”

Reference

  1. Ramey SJ, Yechieli R, Zhao W, et al. Limb‐sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high‐grade, extremity soft‐tissue sarcoma from the NCDB and SEER [published online July 20, 2018]. Cancer Med. doi: 10.1002/cam4.1625

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs